Pamiparib
Pamiparib is a pharmaceutical drug with 24 clinical trials. Currently 6 active trials ongoing. Historical success rate of 88.9%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
9
Early Stage
14
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
66.7%
8 of 12 finished
33.3%
4 ended early
6
trials recruiting
24
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer
Clinical Trials (24)
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer
Study of Pamiparib in Newly Diagnosed and rGBM
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects
A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer
Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy
Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 24